Stryker Corporation (SYK) was Resumed by Barclays to “Underweight” and the brokerage firm has set the Price Target at $107. Barclays advised their investors in a research report released on Apr 11, 2016.
Many Wall Street Analysts have commented on Stryker Corporation. Stryker Corporation was Initiated by Nomura to “Neutral” on Mar 17, 2016. Company shares were Reiterated by Deutsche Bank on Feb 1, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $107 .
On the company’s financial health, Stryker Corporation reported $1.56 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.55. The company had revenue of $2715.00 million for the quarter, compared to analysts expectations of $2714.84 million. The company’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Stryker Corporation closed down -0.29 points or -0.27% at $108.25 with 19,12,587 shares getting traded on Monday. Post opening the session at $108.49, the shares hit an intraday low of $108.17 and an intraday high of $108.94 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 7, 2016, Ronda E Stryker (director) sold 12,000 shares at $108.34 per share price. According to the SEC, on Apr 5, 2016, Katherine Ann Owen (V.P., Strategy & Investor Rel.) sold 10,914 shares at $109.29 per share price. On Mar 15, 2016, Kevin Lobo (Chairman and CEO) sold 25,952 shares at $105.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics Medical and Surgical and Neurotechnology and Spine which help improve patient and hospital outcomes.